VERNIERI, CLAUDIO
VERNIERI, CLAUDIO
Dipartimento di Oncologia ed Emato-Oncologia
Real-world progression-free survival 2 with CDK4/6 inhibitors plus endocrine therapy and subsequent line: Results from the multicenter SISTER study
2023 S. Morganti, S. Gandini, E. Nicolo, E. Zattarin, C. Corti, A. Verrazzo, P.P.M.B. Giachetti, C. Sposetti, M.G. Razeti, B.T. Salimbeni, L. Boldrini, A.C. Schianca, R. Caputo, C. Vernieri, E. Munzone, M. Lambertini, M. De Laurentiis, G. Viale, G. Curigliano, C. Criscitiello
The impact of COVID-19 on diagnosis of recurrent breast cancer
2022 S. Di Cosimo, C. Depretto, R. Miceli, P. Baili, S. Ljevar, M. Sant, C. Ferranti, S. Folli, M. Gennaro, F.G. de Braud, C. Vernieri, M.C. De Santis, L. Lozza, A. Vingiani, G. Pruneri, G. Apolone, A. Marchiano, G.P. Scaperrotta
Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab
2022 F. Ligorio, S. Di Cosimo, P. Verderio, C.M. Ciniselli, S. Pizzamiglio, L. Castagnoli, M. Dugo, B. Galbardi, R. Salgado, S. Loi, S. Michiels, T. Triulzi, E. Tagliabue, S. El-Abed, M. Izquierdo, E. de Azambuja, P. Nuciforo, J. Huober, L. Moscetti, W. Janni, M.A. Coccia-Portugal, P.A. Corsetto, A. Belfiore, D. Lorenzini, M.G. Daidone, A. Vingiani, L. Gianni, S.M. Pupa, G. Bianchini, G. Pruneri, C. Vernieri
Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin
2022 E. Zattarin, F. Nichetti, F. Ligorio, L. Mazzeo, R. Lobefaro, G. Fuca, G. Peverelli, A. Vingiani, G. Bianchi, V, G. Capri, F. de Braud, C. Vernieri
PillarX: A Microfluidic Device to Profile Circulating Tumor Cell Clusters Based on Geometry, Deformability, and Epithelial State
2022 B.J. Green, M. Marazzini, B. Hershey, A. Fardin, Q. Li, Z. Wang, G. Giangreco, F. Pisati, S. Marchesi, A. Disanza, E. Frittoli, E. Martini, S. Magni, G.V. Beznoussenko, C. Vernieri, R. Lobefaro, D. Parazzoli, P. Maiuri, K. Havas, M. Labib, S. Sigismund, P.P.D. Fiore, R.H. Gunby, S.O. Kelley, G. Scita
Aromatase Inhibitors in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: Profiles of Psychological Symptoms and Quality of Life in Different Patient Clusters
2021 C. Borreani, S. Alfieri, G. Infante, R. Miceli, P. Mariani, M. Bosisio, C. Vernieri, G.V. Bianchi, G. Capri
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET)
2021 C. Vernieri, F. Nichetti, L. Lalli, L. Moscetti, C.A. Giorgi, G. Griguolo, A. Marra, G. Randon, C.G. Rea, F. Ligorio, S. Scagnoli, C. De Angelis, C. Molinelli, A. Fabbri, E. Ferraro, D. Trapani, A. Milani, E. Agostinetto, O. Bernocchi, G. Catania, A. Vantaggiato, M. Palleschi, A. Moretti, D. Basile, M. Cinausero, A. Ajazi, L. Castagnoli, S. Lo Vullo, L. Gerratana, F. Puglisi, N. La Verde, G. Arpino, A. Rocca, M. Ciccarese, R. Pedersini, A. Fabi, D. Generali, A. Losurdo, F. Montemurro, G. Curigliano, L. Del Mastro, A. Michelotti, E. Cortesi, V. Guarneri, G. Pruneri, L. Mariani, F. de Braud
Endosomal trafficking and DNA damage checkpoint kinases dictate survival to replication stress by regulating amino acid uptake and protein synthesis
2021 A. Ajazi, C. Bruhn, G. Shubassi, C. Lucca, E. Ferrari, A. Cattaneo, A. Bachi, N. Manfrini, S. Biffo, E. Martini, S. Minucci, C. Vernieri, M. Foiani
Prognostic role of body mass index (BMI) in patients with Human Epidermal growth factor Receptor 2 (HER2)epositive early breast cancer treated with adjuvant trastuzumab-containing chemotherapy
2020 F. Ligorio, L. Zambelli, A. Bottiglieri, L. Castagnoli, E. Zattarin, R. Loberfaro, A. Belfiore, A. Vingiani, G. Pruneri, G. Bianchi, G. Capri, S. Pupa, F. de Braud, C. Vernieri
Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers
2020 M. Di Tano, F. Raucci, C. Vernieri, I. Caffa, R. Buono, M. Fanti, S. Brandhorst, G. Curigliano, A. Nencioni, F. de Braud, V.D. Longo
Association between the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and efficacy of CDK 4/6 inhibitors in advanced breast cancer: The observational multicenter Italian PALMARES study
2020 E. Zattarin, C. Fabbroni, F. Ligorio, A. Marra, C. Corti, O. Bernocchi, M. Sirico, D. Generali, G. Curigliano, G. Bianchi, G. Capri, L. Rivoltini, F. De Braud, C. Vernieri
Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders
2020 W.-. Kong, C. Vernieri, M. Foiani, J.-. Jiang
Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications
2020 E. Zattarin, R. Leporati, F. Ligorio, R. Lobefaro, A. Vingiani, G. Pruneri, C. Vernieri
Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs)
2019 C. Vernieri, S. Pusceddu, G. Fucà, P. Indelicato, G. Centonze, L. Castagnoli, E. Ferrari, A. Ajazi, S. Pupa, S. Casola, M. Foiani, V. Mazzaferro, G. Pruneri, M. Milione, F. de Braud
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors
2019 G. Fucà, G. Galli, M. Poggi, G. Lo Russo, C. Proto, M. Imbimbo, R. Ferrara, N. Zilembo, M. Ganzinelli, A. Sica, V. Torri, M. Colombo, C. Vernieri, A. Balsari, F. de Braud, M. Garassino, D. Signorelli
Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study
2019 G. Fucà, L. Mariani, S. Lo Vullo, G. Galli, R. Berardi, M. Di Nicola, C. Vernieri, D. Morelli, K. Dotti, I. Fiordoliva, S. Rinaldi, C. Gavazzi, F. Pietrantonio, M. Platania, F. de Braud
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives
2019 C. Vernieri, M. Milano, M. Brambilla, A. Mennitto, C. Maggi, M.S. Cona, M. Prisciandaro, C. Fabbroni, L. Celio, G. Mariani, G.V. Bianchi, G. Capri, F. de Braud
Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma : the FAME Trial
2019 C. Vernieri, D. Signorelli, G. Galli, M. Ganzinelli, M. Moro, A. Fabbri, E. Tamborini, M. Marabese, E. Caiola, M. Broggini, L. Hollander, R. Gallucci, G. Vandoni, C. Gavazzi, T. Triulzi, M.P. Colombo, A.M. Rizzo, P.A. Corsetto, G. Pruneri, F. de Braud, G. Sozzi, V. Torri, M.C. Garassino
Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer : a Retrospective Comparison of Efficacy and Safety Profiles
2019 C. Vernieri, M. Prisciandaro, M. Milano, M.S. Cona, C. Maggi, M. Brambilla, A. Mennitto, C. Fabbroni, E. Farè, S. Cresta, L. Celio, G. Mariani, G. Bianchi, G. Capri, F. de Braud
Combination of baseline LDH, performance status and age as integrated algorithm to identify solid tumor patients with higher probability of response to anti PD-1 and PD-l1 monoclonal antibodies
2019 M.S. Cona, M. Lecchi, S. Cresta, S. Damian, M. Del Vecchio, A. Necchi, M.M. Poggi, D. Raggi, G. Randon, R. Ratta, D. Signorelli, C. Vernieri, F. de Braud, P. Verderio, M. Di Nicola